Blueprint Medicines (NASDAQ:BPMC) Lifted to “Strong-Buy” at Baird R W
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. BPMC has been the topic of a number of other reports. Barclays upped their price target on Blueprint Medicines from $75.00 to […]
More Stories
DOJ to End Police Reform Agreements, Investigations Into Departments
By Jack Phillips The U.S. Department of Justice (DOJ) has announced it will end its agreements to secure court-approved settlements...
Mortgage Demand Slumps, Rates Rise to Highest Level Since February
By Andrew Moran Demand for mortgages declined last week as interest rates rose to their highest level since February, new...
Congressional Stock Trading Significantly Erodes Public Trust, Study Finds
By City News Service SAN DIEGO—Trading stocks while in office severely erodes the trust of the American people, regardless of...
Senate Passes ‘No Tax on Tips Act’ in Unanimous Vote
By Katabella Roberts Lawmakers in the Republican-led Senate on Tuesday passed a proposal to eliminate federal taxes on tips, moving...
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Shake Shack Inc. (NYSE:SHAK)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Shake Shack Inc. (NYSE:SHAK – Free Report) by 3.9% in...
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Holdings in Boot Barn Holdings, Inc. (NYSE:BOOT)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Boot Barn Holdings, Inc. (NYSE:BOOT – Free Report) by 4.2%...